Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
At one time the biological effects of cAMP
2020-07-22

At one time, the biological effects of cAMP were thought to be mediated exclusively by Protein Kinase A (PKA). Consistent with this, PKA inhibitors have been shown to reverse the effects of cAMP-elevating agents on VSMC proliferation [5]. However, we recently reported that cAMP-mediated inhibition o
-
Importantly we observed significantly the reduced myocardial
2020-07-22

Importantly, we observed significantly the reduced myocardial infarct size, the improved left ventricular function and the inhibited fibrosis after I/R with oral GA-BH4 supplementation before ischemia (Fig. 1, Fig. 2, Fig. 3). Usually, there is a view that the antioxidation induced by reducing agent
-
Among the Ub interactions observed
2020-07-22

Among the ~Ub interactions observed in the HOIP structure is one that involves a RING2 domain (from the non-cognate HOIP) [47]. A similar binding interaction was defined between HHARI RING2 and the hydrophobic patch on Ub by NMR [54]. HHARI RING2 mutations that ablate the interaction inhibit formati
-
Having generated synthetic cytokines and synthetic cytokine
2020-07-21

Having generated synthetic cytokines and synthetic cytokine receptors, the logical next step has been to design fully synthetic cytokine/cytokine receptor systems, modifying either cytokine/cytokine receptor binding interfaces or cytokine-unrelated combinations of substances and their binding domain
-
For the first time the V carinata transcriptome was analyzed
2020-07-21

For the first time, the V. carinata transcriptome was analyzed and its transcript coding sequences comprehensively characterized. The non-redundant contigs encoding putative CysPs were identified and their neuraminidase inhibitor patterns in different tissues were investigated. Our study show that
-
Kim et al reported for bioactive compounds
2020-07-21

Kim et al. reported for bioactive compounds originating from the endemic species in Korea, the hexane and EtOAc fractions of the MeOH extracts from the roots of Dystaenia takeshimana (Nakai) Kitagawa (Umbelliferae) showed cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) dual inhibitory activity b
-
br Discussion The membrane PVase activity components were
2020-07-21

Discussion The membrane PVase activity components were discriminated in this work by pre-incubating with PMSF, mipafox, paraoxon or PMSF + mipafox to irreversibly inhibitPVase activity to discriminate the enzymatic components, (EPα, EPβ, EPγ and EPδ). The concentrations employed to discriminate t
-
Enzyme activity loss during the hydrolysis process
2020-07-21

Enzyme activity loss during the hydrolysis process has traditionally been associated with thermal, mechanical, and/or chemical mechanisms (Okino et al., 2013, Ye et al., 2012, Zhang et al., 2010). Due to the recent discovery of enzyme activity loss due to interaction with substrate, it is important
-
Introduction The annual global market of industrial
2020-07-21

Introduction The annual global market of industrial Fluorouracil is reported to be billions of USD [1], [2], [3], [4], [5], [6], [7], and impacts commercial sectors that include energy, animal feed, household products, food processing and pharmaceuticals [1], [2], [5], [6]. Enzymatic processing is
-
br Management of Hypertension The aim of treating
2020-07-21

Management of Hypertension The aim of treating HT is to reduce the risk of adverse cardiovascular outcomes: mainly coronary artery disease, stroke, and death. For this reason, the decision whether to initiate pharmacological treatment or not will depend not only on BP values, but also on the over
-
Dual inhibition of ACE and
2020-07-21

Dual inhibition of ACE and NEP as a strategy for treating hypertension has been extensively investigated, including contributions from these laboratories through the discovery of Sampatrilat . Given that both targets are related zinc metalloproteinases, dual enzyme inhibition can be achieved within
-
The redox sensitive transcription factor NF B is reported to
2020-07-21

The redox sensitive transcription factor NF-κB is reported to play a crucial role in the COPD pathogenesis via up regulating the expression of several cytokines, chemokines, growth factors, and adhesion molecules [71]. Incidentally, we and others have shown that PARP-1 modulates the NF-κB activation
-
The majority of APC C subunits form a giant
2020-07-21

The majority of APC/C subunits form a giant scaffold, which was originally named the arc lamp, based on its shape when viewing APC/C from one side (Figure 1 and Box 1) [24]. The scaffold consists of two modules: the TPR lobe resembles the curved post and lamp, and the platform resembles the Bestatin
-
To examine the influence of aromatic motifs on
2020-07-21

To examine the influence of aromatic motifs on the bridging lysine esters we analysed DNA alkylating activity of the set of compounds 1–6. The lysine derivatives were chosen as it is relatively easy to prepare different esters and thereby study the impact of different groups on the reactivity toward
-
prostanoid receptors ELUXA HM EMSI is an ongoing
2020-07-20

ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp
15893 records 794/1060 page Previous Next First page 上5页 791792793794795 下5页 Last page